Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008] — Jordi Bruix (2018) | RDL Network
Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008]
Josep M. Llovet, Serafino Ricci, Vincenzo Mazzaferro, P Hilgard, Jean‐Luc Raoul, Stefan Zeuzem, Melanie Poulin-Costello, M. Moscovici, D. Voliotis, Jordi Bruix
Discussion(0)
No comments yet. Be the first to comment.